Dr. Mikhail Blagosklonny is an oncologist and scientist whose research focuses on cancer and aging. He was also served as a Roswell Park Cancer Institute professor of oncology. A native of Russia, Dr. Blagosklonny attended St. Petersburg’s First Pavlov State Medical University. At the university he got an M.D. in internal medicine as well as a PhD in cardiology and experimental medicine. In 2002, Blagosklonny was hired at New York Medical College as an assistant professor. He then worked at Ordway Research Institute as a senior scientist. He left in 2009 to become an oncology professor with Roswell Park Cancer Institute.
Dr. Blagosklonny is known for his research on cancer, targeted cancer therapies that can eliminate damage to normal cells, the mechanisms underlying aging as well as anti-aging drugs. Dr. Mikhail Blagosklonny has also received attention for the hypothesis he formulated about TOR signaling’s possible role in aging and cancer. He has also proposed that the popular cancer drug rapamycin is potentially an effective treatment for life extension. Dr. Blagosklonny is considered to be among the most vocal advocates for rapamycin’s use in longevity research. A recent study showing rapamycin extends the life of mice seems to validate his belief and more information click here.
A very active writer, Dr. Blagosklonny has had over 270 papers published in peer-reviewed journals. Some of the topics he has written on include:
Aging: Ros or tor
Molecular effects of paclitaxel: myths and reality (a critical review)
The restriction point of the cell cycle
“TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists”.
“MTOR and autophagy: converging on senescence or quiescence”
“Matching targets for selective cancer therapy”
“Oncogenic resistance to growth-limiting conditions”
“Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells”.
While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts and learn more about Mikhail.
Dr. Blagosklonny also has over 25,000 citations. This gives him an 83 h-index. Mikhail Blaglosklonny in also very much involved in editorial activities. He is Oncotarget, Cell Cycle and Aging’s editor-in-chief. Blagosklonny is also Cancer Biology & Therapy’s associate editor as well as a member of Cell Death & Differentiation’s editorial board. He’s also associate editor of the American Journal of Pathology, PLOS ONE and International Journal of Cancer. Mikhail Blagosklonny is an accomplished physician. He’s held a number of top-notch positions and has risen through the ranks over his more than 20 years working in research, as a physician and an educator.
Mikhail Blagosklonny’s works on many important topics. They include cellular and molecular biology, ontogenesis, signal transduction, tumor suppressors, apoptosis, cell cycle, anticancer therapeutics and drug resistance and normal cells selective protection. Dr. Blagosklonny has also written on aging hyperfunction theory, cell cyclotherapy as well as chemotherapeutic engineering. He has a keen interest in oncology, believes controlling aging and cancer is possible and cancer can be cured. Dr. Mikhail Blagosklonny’s love for humanity and vision of a disease-free society led him into a career in science and Mikhail’s lacrosse camp.
Other Reference: https://www.crunchbase.com/person/mikhail-blagosklonny